Lifeline Biotechnologies, Inc. LBTN) announced today that they are providing additional OvaScope(TM) equipment
for the continuation of patient testing, under the direction of Professor
Kefah Mokbel, in the United Kingdom. The OvaScope is a microendoscope that
has been designed by the Company to assist in the early detection of
ovarian cancer.
Lifeline previously announced the Company's successful initial testing of
the OvaScope(TM) in surgical procedures. The Company plans to continue
testing with the objective of obtaining CE certification and clearance to
initially market the OvaScope(TM) in the International Medical Markets.
Upon successful completion patient testing The Company will submit testing
results to the FDA and seek clearance for marketing the device in the
United States.
According to the Center for Disease Control (CDC) website, there are
approximately 25,600 cases of ovarian cancers detected in the US each year.
The unfortunate fact is that there is no FDA approved method for the early
detection of ovarian cancer that is available to the medical community
today. Consequently, ovarian cancer is not usually detected until the very
late stages of the disease and at a time when treatments are less
successful with only a 30% survival rate.
"The initial product testing has been successfully completed involving ten
female patients in a gynecological oncology unit. The OvaScope(TM)
identified all patients with peritoneal disease. The results were very
encouraging, and we have expectations that we will achieve similar results
in our second round of testing," stated Jim Holmes, Lifeline's CEO.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative medical
technologies committed to the improvement of the quality of life through
exceptional health care systems. These technologies focus on prevention,
early detection, diagnosis and quick recovery of a number of disease
conditions. The company's Cancer Detection technologies deal with
cutting-edge innovation to assist practicing physicians in the delivery of
quality medical care. The MastaScope(TM) is used in the early detection of
cancer and other abnormalities of the breast. The MastaScope(TM) has
completed development and has entered the marketplace in the US and
internationally. The First Warning System(TM) for assisting in the early
detection of breast cancer and the OvaScope(TM) for assisting in the early
detection of ovarian cancer are continuing to be developed by the company.
More information is available at the company's website: www.lbti.com.
Safe Harbor
This release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 27E of the Securities
Act of 1934. Statements contained in this release that are not historical
facts may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected or
suggested herein due to certain risks and uncertainties including, without
limitation, ability to obtain financing and regulatory and shareholder
approval for anticipated actions.
Contact:
Big Apple Consulting USA, Inc.
for Lifeline Biotechnologies, Inc.
Investor Relations
Rodney Marvel
407-884-0444
1-866-The-Apple
A True Wise Person Realizes How Much They DON’T Know, Rather Than How Much They DO..
